This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sensitivity analysis
Sensitivity analysis was carried out using threshold analysis.
Estimated benefits used in the economic analysis
Incremental QALYs per patient (costs and benefits discounted at 5%) for: hysterectomy for benign neoplasms, age 30 were 0.11; hysterectomy for benign neoplasms, age 40 were 0.08; hysterectomy for benign neoplasms, age 50 were 0.08; hysterectomy for menstruation disorders, age 30 were 0.11; hysterectomy for menstruation disorders, age 40 were 0.08; hysterectomy for abnormal anatomy, age 30 were 0.16; hysterectomy for abnormal anatomy, age 40 were 0.15; hysterectomy for abnormal anatomy, age 50 were 0.17; hysterectomy for abnormal anatomy, age 60 were 0.11; hysterectomy for cervical disease, age 30 were 0.11; hysterectomy for cervical disease, age 40 were 0.08; hysterectomy, oophorectomy and oestrogen replacement therapy for benign neoplasms, age 30 were 0.16; hysterectomy, oophorectomy and oestrogen replacement therapy for benign neoplasms, age 40 were 0.15; hysterectomy, oophorectomy and oestrogen replacement therapy for benign neoplasms, age 50 were 0.10; hysterectomy, oophorectomy and oestrogen replacement therapy for menstruation disorders, age 30 were 0.16; hysterectomy, oophorectomy and oestrogen replacement therapy for menstruation disorders, age 40 were 0.15; hysterectomy, oophorectomy and oestrogen replacement therapy for abnormal anatomy, age 30 were 0.20; hysterectomy, oophorectomy and oestrogen replacement therapy for abnormal anatomy, age 40 were 0.22; hysterectomy, oophorectomy and oestrogen replacement therapy for abnormal anatomy, age 50 were 0.18; hysterectomy, oophorectomy and oestrogen replacement therapy for abnormal anatomy, age 60 were 0.19; hysterectomy, oophorectomy and oestrogen replacement therapy for cervical disease, age 30were 0.16; hysterectomy, oophorectomy and oestrogen replacement therapy for cervical disease, age 40 were 0.15; hysterectomy, oophorectomy and oestrogen replacement therapy for endometriosis, age 30 were 0.16 and;
